ATE339957T1 - Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs - Google Patents

Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Info

Publication number
ATE339957T1
ATE339957T1 AT00973002T AT00973002T ATE339957T1 AT E339957 T1 ATE339957 T1 AT E339957T1 AT 00973002 T AT00973002 T AT 00973002T AT 00973002 T AT00973002 T AT 00973002T AT E339957 T1 ATE339957 T1 AT E339957T1
Authority
AT
Austria
Prior art keywords
breast cancer
tyrosine kinase
egfr tyrosine
kinase inhibitors
treat breast
Prior art date
Application number
AT00973002T
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE339957T1 publication Critical patent/ATE339957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00973002T 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs ATE339957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE339957T1 true ATE339957T1 (de) 2006-10-15

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973002T ATE339957T1 (de) 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Country Status (21)

Country Link
US (1) US7553815B1 (de)
EP (1) EP1272188B1 (de)
JP (1) JP2003513035A (de)
KR (1) KR100785359B1 (de)
CN (1) CN1197577C (de)
AT (1) ATE339957T1 (de)
AU (1) AU779190B2 (de)
BR (1) BR0015194A (de)
CA (1) CA2389411C (de)
CY (1) CY1106285T1 (de)
DE (1) DE60030889T2 (de)
DK (1) DK1272188T3 (de)
ES (1) ES2275556T3 (de)
GB (1) GB9925958D0 (de)
IL (1) IL149176A0 (de)
MX (1) MXPA02004272A (de)
NO (1) NO323206B1 (de)
NZ (1) NZ518696A (de)
PT (1) PT1272188E (de)
WO (1) WO2001032155A2 (de)
ZA (1) ZA200203431B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1282443T3 (da) 2000-05-19 2010-01-04 Genentech Inc Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
ATE547708T1 (de) 2002-06-05 2012-03-15 Cedars Sinai Medical Center Verfahren zur handhabung der kinasehemmertherapie
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
RU2370494C2 (ru) 2003-09-19 2009-10-20 Астразенека Аб Производные хиназолина
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5767122B2 (ja) 2009-03-11 2015-08-19 アルデア バイオサイエンシズ，インコーポレイティド 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2536748B1 (de) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
CA2842375A1 (en) 2011-08-17 2013-02-21 Erica Jackson Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2014126098A (ru) 2011-11-30 2016-01-27 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
DK0817775T3 (da) * 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
JP4146514B2 (ja) * 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
JP2002515511A (ja) * 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
CN101512597B (zh) 2006-08-28 2013-02-06 Tp视觉控股有限公司 图像增强方法和设备

Also Published As

Publication number Publication date
ES2275556T3 (es) 2007-06-16
NZ518696A (en) 2004-12-24
AU779190B2 (en) 2005-01-13
EP1272188A2 (de) 2003-01-08
NO20022065D0 (no) 2002-04-30
ZA200203431B (en) 2003-02-26
US7553815B1 (en) 2009-06-30
DE60030889T2 (de) 2007-04-05
CY1106285T1 (el) 2011-10-12
EP1272188B1 (de) 2006-09-20
CA2389411A1 (en) 2001-05-10
NO323206B1 (no) 2007-01-22
BR0015194A (pt) 2002-06-18
NO20022065L (no) 2002-06-24
JP2003513035A (ja) 2003-04-08
GB9925958D0 (en) 1999-12-29
CN1197577C (zh) 2005-04-20
KR100785359B1 (ko) 2007-12-18
CA2389411C (en) 2009-09-01
DK1272188T3 (da) 2007-01-29
MXPA02004272A (es) 2003-08-20
PT1272188E (pt) 2007-01-31
WO2001032155A2 (en) 2001-05-10
KR20020064306A (ko) 2002-08-07
WO2001032155A3 (en) 2002-05-10
IL149176A0 (en) 2002-11-10
DE60030889D1 (de) 2006-11-02
AU1155901A (en) 2001-05-14
CN1387437A (zh) 2002-12-25

Similar Documents

Publication Publication Date Title
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
MY151032A (en) Treatment of tnf? related disorders
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
TNSN04015A1 (en) Combination therapy for the treatment of cancer
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE486594T1 (de) Methode zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272188

Country of ref document: EP

REN Ceased due to non-payment of the annual fee